Discovery and Validation of New Molecular Targets in Treating Dyslipidemia: The Role of Human Genetics

Trends in Cardiovascular Medicine

Volumn 19, Issue 6, 2009, Pages 195-201

  Khera, Amit V ^a   Rader, Daniel J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN A1; APOLIPOPROTEIN A4; APOLIPOPROTEIN A5; APOLIPOPROTEIN B100; APOLIPOPROTEIN C3; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; ROSUVASTATIN; TORCETRAPIB; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG TARGETING; DYSLIPIDEMIA; ENZYME INHIBITION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; NONHUMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTILIPEMIC AGENTS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DRUG DISCOVERY; DYSLIPIDEMIAS; GENETIC PREDISPOSITION TO DISEASE; GENOMICS; HUMANS; LIPID METABOLISM; LIPOPROTEIN(A); MENDELIAN RANDOMIZATION ANALYSIS; PHENOTYPE; POLYMORPHISM, GENETIC; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 77649086392     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tcm.2009.12.003     Document Type: Review

References (55)

1. Abifadel M., Varret M., Rabès J.P., et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34 (2003) 154-156
2. Barter P., Gotto A.M., LaRosa J.C., et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 357 (2007) 1301-1310
3. Barter P.J., Caulfield M., Eriksson M., et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357 (2007) 2109-2122
4. Benlian P., De Gennes J.L., Foubert L., et al. Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene. N Engl J Med 335 (1996) 848-854
5. Brown M.S., and Goldstein J.L. A receptor-mediated pathway for cholesterol homeostasis. Science 232 (1986) 34-47
6. Calabresi L., Baldassarre D., Castelnuovo S., et al. Functional lecithin: cholesterol acyltransferase is not required for efficient atheroprotection in humans. Circulation 120 (2009) 628-635
7. Chan J.C., Piper D.E., Cao Q., et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci U S A 106 (2009) 9820-9825
8. Clarke R., Peden J.F., Hopewell H.C., et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 361 (2009) 2518-2528
9. Cobbaert C., Jukema J.W., Zwinderman A.H., et al. Modulation of lipoprotein(a) atherogenicity by high density lipoprotein cholesterol levels in middle-aged men with symptomatic coronary artery disease and normal to moderately elevated serum cholesterol. Regression Growth Evaluation Statin Study (REGRESS) Study Group. J Am Coll Cardiol 30 (1997) 1491-1499
10. Cohen J.C., Boerwinkle E., Mosley Jr. T.H., and Hobbs H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354 (2006) 1264-1272
11. Curb J.D., Abbott R.D., Rodriguez B.L., et al. A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly. J Lipid Res 45 (2004) 948-953
12. Deb A., and Caplice N.M. Lipoprotein(a): new insights into mechanisms of atherogenesis and thrombosis. Clin Cardiol 27 (2004) 258-264
13. deGoma E.M., deGoma R.L., and Rader D.J. Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol 51 (2008) 2199-2211
14. Emerging Risk Factors Collaboration, Erqou S., Kaptoge S., et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 302 (2009) 412-423
15. Ford E.S., Ajani U.A., Croft J.B., et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med 356 (2007) 2388-2398
16. Frank-Kamenetsky M., Grefhorst A., Anderson N.N., et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A 105 (2008) 11915-11920
17. Frikke-Schmidt R., Nordestgaard B.G., Stene M.C., et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA 299 (2008) 2524-2532
18. Garber A.M.L. An uncertain future for cardiovascular drug development?. N Engl J Med 360 (2009) 1169-1171
19. Gordon D.J. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79 (1989) 8-15
20. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
21. Guyton J.R., Blazing M.A., Hagar J., et al. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group. Arch Intern Med 160 (2000) 1177-1184
22. Horton J.D., Cohen J.C., and Hobbs H.H. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res 50 (2009) S172-177
23. Kamstrup P.R., Tybjaerg-Hansen A., Steffensen R., and Nordestgaard B.G. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 301 (2009) 2331-2339
24. Kastelein J.J., Akdim F., Stroes E.S., et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 358 (2008) 1431-1443
25. Katan M.B. Apolipoprotein E isoforms, serum cholesterol, and cancer. Lancet 327 (1986) 507-508
26. Kathiresan S., and Myocardial Infarction Genetics Consortium. A PCSK9 missense variant associated with a reduced risk of early-onset myocardial infarction. N Engl J Med 358 (2008) 2299-2300
27. Kathiresan S., Melander O., Anevski D., et al. Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med 358 (2008) 1240-1249
28. Kathiresan S., Melander O., Guiducci C., et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet 40 (2008) 189-197
29. Kathiresan S., Willer C.J., Peloso G.M., et al. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet 41 (2009) 56-65
30. Keech A., Simes R.J., Barter P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005) 1849-1861
31. LaRosa J.C., He J., and Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 282 (1999) 2340-2346
32. Miller M., Cannon C.P., Murphy S.A., et al. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 51 (2008) 724-730
33. Myocardial Infarction Genetics Consortium, Kathiresan S., Voight B.F., et al. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet 41 (2009) 334-341
34. Nordestgaard B.G., Benn M., Schnohr P., et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 298 (2007) 299-308
35. Pharmaceutical Research and Manufacturers of America. Report: medicines in development for heart disease and stroke. Accessed June 27, 2009, at (2009). http://www.phrma.org/files/Heart%202009.pdf
36. Pollin T.I., Damcott C.M., Shen H., et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science 322 (2008) 1702-1705
37. Qasim A., and Rader D.J. Human genetics of variation in high-density lipoprotein cholesterol. Curr Atheroscler Rep 8 (2006) 198-205
38. Rader D.J., Alexander E.T., Weibel G.L., et al. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res 50 (2009) S189-S194
39. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 (2008) 2195-2207
40. Ridker P.M., Danielson E., Fonseca F.A., et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 373 (2009) 1175-1182
41. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
42. Samani N.J., Erdmann J., Hall A.S., et al. Genomewide association analysis of coronary artery disease. N Engl J Med 357 (2007) 443-453
43. Sarwar N., Danesh J., Eiriksdottir G., et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 115 (2007) 450-458
44. Schunkert H., and Samani N.J. Elevated C-reactive protein in atherosclerosis-chicken or egg?. N Engl J Med 359 (2008) 1953-1955
45. Shimada M., Ishibashi S., Inaba T., et al. Suppression of diet-induced atherosclerosis in low density lipoprotein receptor knockout mice overexpressing lipoprotein lipase. Proc Natl Acad Sci U S A 93 (1996) 7242-7246
46. Smith G.D., Timpson N., and Ebrahim S. Strengthening causal inference in cardiovascular epidemiology through Mendelian randomization. Ann Med 40 (2008) 524-541
47. Taylor A.J., Villines T.C., Stanek E.J., et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 361 (2009) 2113-2122
48. Thanassoulis G., and O'Donnell C.J. Mendelian randomization: nature's randomized trial in the post-genome era. JAMA 301 (2009) 2386-2388
49. Thompson A., Di Angelantonio E., Sarwar N., et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA 299 (2008) 2777-2788
50. Trégouët D.A., König I.R., Erdmann J., et al. Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat Genet 41 (2009) 283-285
51. Willer C.J., Sanna S., Jackson A.U., et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet 40 (2008) 161-169
52. Yagyu H., Ishibashi S., Chen Z., et al. Overexpressed lipoprotein lipase protects against atherosclerosis in apolipoprotein E knockout mice. J Lipid Res 40 (1999) 1677-1685
53. Yu K.C., and Cooper A.D. Postprandial lipoproteins and atherosclerosis. Front Biosci 6 (2001) D332-D354
54. Zacho J., Tybjaerg-Hansen A., Jensen J.S., et al. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 359 (2008) 1897-1908
55. Zhong S., Sharp D.S., Grove J.S., et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 97 (1996) 2917-2923